help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Litchfield, W. R.
Right arrow Articles by Dluhy, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Litchfield, W. R.
Right arrow Articles by Dluhy, R. G.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*DEXAMETHASONE
Medline Plus Health Information
*Steroids
The Journal of Clinical Endocrinology & Metabolism Vol. 82, No. 11 3570-3573
Copyright © 1997 by The Endocrine Society


Original Studies

Evaluation of the Dexamethasone Suppression Test for the Diagnosis of Glucocorticoid-Remediable Aldosteronism1

W. Reid Litchfield, Maria I. New, Caroline Coolidge, Richard P. Lifton and Robert G. Dluhy

Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School (W.R.L., C.C., R.G.D.), Boston, Massachusetts 02115; the Department of Medicine, New York Hospital and Cornell Medical Center (M.I.N.), New York, New York 10021; and the Departments of Medicine and Genetics, Boyer Center for Molecular Medicine (R.P.L.), Yale University School of Medicine, New Haven, Connecticut 06510

Address all correspondence and requests for reprints to: Dr. W. Reid Litchfield, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, 221 Longwood Ave RFB-2, Boston, Massachusetts 02115.

Glucocorticoid-remediable aldosteronism (GRA) is a rare form of inherited hypertension caused by a characteristic gene duplication. With the advent of definitive genetic testing for GRA, the performance of the traditional screening test for GRA, the dexamethasone suppression test (DST), can be evaluated. We compared the DST to direct genetic testing in 24 patients referred for genetic screening for GRA (12 GRA positive and 12 GRA negative) based on clinical and biochemical findings, DST, and family history. Plasma aldosterone was measured before and after oral dexamethasone administration to determine the extent to which aldosterone was suppressed by glucocorticoids in each patient group. The results of the DST in these subjects were also compared to those in 19 historical patients with primary aldosteronism [4 bilateral hyperplasia and 15 aldosterone-producing adenoma (APA)] reported previously. The DST differentiated GRA-positive from GRA-negative patients with 92% sensitivity and 100% specificity. Cutoffs based on the post-DST plasma aldosterone level (<4 ng/dL) or percent suppression compared to baseline (>80%) were equally effective in correctly diagnosing GRA (only one GRA-positive patient would have been incorrectly diagnosed). However, DST in 15 APA patients revealed that 33% had greater than 80% suppression of aldosterone, and 1 had aldosterone levels below 4 ng/dL.

We conclued that a post-DST aldosterone level below 4 ng/dL will correctly diagnose GRA patients with high sensitivity and specificity. Suppression compared to baseline can be misleading, as evidenced by the results in APA patients and referred subjects who genetically screened negative.




This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
O. Vonend, C. Altenhenne, N. J. Buchner, G. Dekomien, C. Maser-Gluth, S. M. Weiner, L. Sellin, S. Hofebauer, J. T. Epplen, and L. C. Rump
A German family with glucocorticoid-remediable aldosteronism
Nephrol. Dial. Transplant., April 1, 2007; 22(4): 1123 - 1130.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
G. Mansmann, J. Lau, E. Balk, M. Rothberg, Y. Miyachi, and S. R. Bornstein
The Clinically Inapparent Adrenal Mass: Update in Diagnosis and Management
Endocr. Rev., April 1, 2004; 25(2): 309 - 340.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. E. Fardella, M. Pinto, L. Mosso, C. Gomez-Sanchez, J. Jalil, and J. Montero
Genetic Study of Patients with Dexamethasone-Suppressible Aldosteronism without the Chimeric CYP11B1/CYP11B2 Gene
J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4805 - 4807.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
M. Stowasser, R. D Gordon, J. C Rutherford, N. Z Nikwan, N. Daunt, and G. J Slater
Review: Diagnosis and management of primary aldosteronism
Journal of Renin-Angiotensin-Aldosterone System, September 1, 2001; 2(3): 156 - 169.
[PDF]


Home page
HypertensionHome page
L. Mosso, C. E. Gomez-Sanchez, M. F. Foecking, and C. Fardella
Serum 18-Hydroxycortisol in Primary Aldosteronism, Hypertension, and Normotensives
Hypertension, September 1, 2001; 38(3): 688 - 691.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. E. Fardella, L. Mosso, C. Gómez-Sánchez, P. Cortés, J. Soto, L. Gómez, M. Pinto, A. Huete, E. Oestreicher, A. Foradori, et al.
Primary Hyperaldosteronism in Essential Hypertensives: Prevalence, Biochemical Profile, and Molecular Biology
J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 1863 - 1867.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
Glucocorticoid-Remediable Aldosteronism
J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4341 - 4344.
[Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Stowasser, P. R. Huggard, T. R. Rossetti, A. W. Bachmann, and R. D. Gordon
Biochemical Evidence of Aldosterone Overproduction and Abnormal Regulation in Normotensive Individuals with Familial Hyperaldosteronism Type I
J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 4031 - 4036.
[Abstract] [Full Text]


Home page
ANN INTERN MEDHome page
S. R. Bornstein, C. A. Stratakis, and G. P. Chrousos
Adrenocortical Tumors: Recent Advances in Basic Concepts and Clinical Management
Ann Intern Med, May 4, 1999; 130(9): 759 - 771.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. Mulatero, F. Veglio, C. Pilon, F. Rabbia, C. Zocchi, P. Limone, M. Boscaro, N. Sonino, and F. Fallo
Diagnosis of Glucocorticoid-Remediable Aldosteronism in Primary Aldosteronism: Aldosterone Response to Dexamethasone and Long Polymerase Chain Reaction for Chimeric Gene
J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2573 - 2575.
[Abstract] [Full Text]


Home page
HypertensionHome page
W. R. Litchfield, B. F. Anderson, R. J. Weiss, R. P. Lifton, and R. G. Dluhy
Intracranial Aneurysm and Hemorrhagic Stroke in Glucocorticoid-remediable Aldosteronism
Hypertension, January 1, 1998; 31(1): 445 - 450.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1997 by The Endocrine Society